Latest News On FDA

Latest KFF Health News Stories

KFF Health News' 'What the Health?': The Long Road to Reining In Short-Term Plans 

Podcast

President Biden made good on a campaign promise this week with a proposal that would limit short-term health insurance plans that boast low premiums but also few benefits. Meanwhile, the Supreme Court’s decision to outlaw affirmative action programs could set back efforts to diversify the nation’s medical workforce. Alice Miranda Ollstein of Politico, Amy Goldstein of the Washington Post, and Rachel Cohrs of Stat News join KFF Health News’ chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Bram Sable-Smith, who reported the latest KFF Health News-NPR “Bill of the Month” about how a hospital couldn’t track down a patient, but a debt collector could.

KFF Health News' 'What the Health?': The Crisis Is Officially Ending, but Covid Confusion Lives On

Podcast

The public health emergency declaration for covid-19 ends May 11, ushering in major changes in how Americans can access and pay for the vaccines, treatments, and tests particular to the culprit coronavirus. But not everyone will experience the same changes, creating a confusing patchwork of coverage — not unlike health coverage for other diseases. Meanwhile, outside advisers to the FDA formally recommended allowing a birth control pill to be sold without a prescription. If the FDA follows the recommendation, it would represent the first over-the-counter form of hormonal contraception. Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Julie Rovner to discuss these issues and more. Plus for “extra credit” the panelists suggest health policy stories they read this week they think you should read, too.

KFF Health News' 'What the Health?': The Confusing Fate of the Abortion Pill

Podcast

The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.